Evidence map›Paper›PMID 39931433›Full record

ArticleFrontiers in medicine2024

The immune landscape and viral shedding of Omicron SARS-CoV-2 variants implicate immune escape.

Weilong Zhang, Xiaoyan Gai, Zhonghui Duan, Changjian Yan, Chunyuan Huang, Chaoling Wu, Siping Zheng, Zixiang Lin, Qingtao Zhou, Lili Dai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Weilong Zhang *Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Xiaoyan Gai *Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, and Center for Chronic Airway Diseases, Peking University Health Science Center, Peking University, Beijing, China.
Zhonghui Duan *Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Changjian YanDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Chunyuan HuangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Chaoling WuDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Siping ZhengDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Zixiang LinDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Qingtao ZhouDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, and Center for Chronic Airway Diseases, Peking University Health Science Center, Peking University, Beijing, China.
Lili DaiDepartment of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ping YangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Fang BaoDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Hongmei JingDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
Chao CaiDepartment of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yingmin MaDepartment of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yongchang SunDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, and Center for Chronic Airway Diseases, Peking University Health Science Center, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Three years into the SARS-CoV-2 pandemic, the virus continues to mutate despite widespread vaccination, posing ongoing challenges for epidemic prevention and control. The relationship between viral shedding and immune escape remains under investigation. This study aims to examine the association between viral shedding and immune escape in the BA.4/5 and BF.7 variants. Method: We included 542 patients infected with the Omicron variant from Beijing Xiaotangshan shelter hospital. Based on the viral strain, patients were divided into BA.4/5 group and BF.7 group. Additionally, we categorized patients into rapid viral shedding and slow viral shedding groups according to their viral shedding rates. We explored the relationship between viral shedding and immune-related clinical indicators during this period. Result: Of the 542 patients, 118 were infected with BA.4/5 variant, and 424 were infected with BF.7 variant. The viral shedding duration differed significantly between BA.4/5 and BF.7 groups ( Conclusion: The duration of viral shedding in patients infected with Omicron variants BA.4/5 and BF.7 is not associated with WBC, Hb, Lym, CRP, fever, allergy, or vaccine-related indicators. This lack of association may be attributed to immune escape mechanisms.

Indexed as

COVID-19immune escapeOmicronvaccinationviral shedding

Identifiers

PMID39931433
PMCPMC11808361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.